Akebia Therapeutics, Inc. (AKBA)
NASDAQ$2.1106+0.42 (24.85%)
Market Cap
$368.73M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
434 of 924
Rank in Industry
255 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AKBA Insider Trading Activity
AKBA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $746,256 | 8 | 100 |
Related Transactions
| Hadas Nicole R. | SVP, Chief Legal Officer | 0 | $0 | 1 | $15,140 | $-15,140 |
| Dahan Michel | SVP, Chief Operating Officer | 0 | $0 | 1 | $43,898 | $-43,898 |
| Malabre Richard C | SVP, Chief Accounting Officer | 0 | $0 | 1 | $63,424 | $-63,424 |
| Grund Nicholas | Chief Commercial Officer | 0 | $0 | 1 | $116,804 | $-116,804 |
| Burke Steven Keith | SVP, Chief Medical Officer | 0 | $0 | 2 | $119,136 | $-119,136 |
| Butler John P. | CEO and President | 0 | $0 | 2 | $387,853 | $-387,853 |
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; …
Insider Activity of Akebia Therapeutics, Inc.
Over the last 12 months, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $746,256 worth of Akebia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $517,876 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $344,000 was made by Butler John P. (CEO and President) on 2019‑11‑20.
List of Insider Buy and Sell Transactions, Akebia Therapeutics, Inc.
| 2025-03-03 | Sale | Butler John P. | CEO and President | 46,409 0.0217% | $1.83 | $84,928 | +4.44% | |
| 2025-03-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 7,144 0.0033% | $1.83 | $13,074 | +4.44% | |
| 2025-02-03 | Sale | Butler John P. | CEO and President | 144,250 0.062% | $2.10 | $302,925 | -9.43% | |
| 2025-02-03 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 50,506 0.0217% | $2.10 | $106,063 | -9.43% | |
| 2025-02-03 | Sale | Grund Nicholas | Chief Commercial Officer | 55,621 0.0239% | $2.10 | $116,804 | -9.43% | |
| 2025-02-03 | Sale | Malabre Richard C | SVP, Chief Accounting Officer | 30,202 0.013% | $2.10 | $63,424 | -9.43% | |
| 2024-05-13 | Sale | Dahan Michel | SVP, Chief Operating Officer | 34,840 0.0162% | $1.26 | $43,898 | +15.50% | |
| 2024-05-13 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 12,016 0.0056% | $1.26 | $15,140 | +15.50% | |
| 2024-02-29 | Sale | Butler John P. | CEO and President | 46,570 0.0249% | $1.58 | $73,581 | -7.28% | |
| 2024-02-29 | Sale | Dahan Michel | SVP, Chief Operating Officer | 8,661 0.0046% | $1.58 | $13,684 | -7.28% | |
| 2024-02-29 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 7,169 0.0038% | $1.58 | $11,327 | -7.28% | |
| 2024-02-29 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 5,974 0.0032% | $1.58 | $9,439 | -7.28% | |
| 2024-02-27 | Sale | Butler John P. | CEO and President | 37,733 0.0186% | $1.52 | $57,354 | -10.37% | |
| 2024-02-27 | Sale | Dahan Michel | SVP, Chief Operating Officer | 10,744 0.0053% | $1.52 | $16,331 | -10.37% | |
| 2024-02-27 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 8,367 0.0041% | $1.52 | $12,718 | -10.37% | |
| 2024-02-27 | Sale | Hadas Nicole R. | SVP, Chief Legal Officer | 7,411 0.0036% | $1.52 | $11,265 | -10.37% | |
| 2024-02-01 | Sale | Butler John P. | CEO and President | 46,489 0.0254% | $1.68 | $78,102 | -15.50% | |
| 2024-02-01 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 24,311 0.0133% | $1.68 | $40,842 | -15.50% | |
| 2023-08-25 | Sale | Burke Steven Keith | SVP, Chief Medical Officer | 27,000 0.0145% | $1.15 | $31,050 | +9.57% | |
| 2023-05-25 | Sale | Dahan Michel | SVP, Chief Operating Officer | 95,478 0.0522% | $1.22 | $116,760 | +3.31% |
Total: 136
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Butler John P. | CEO and President | 2557921 1.1724% | $4.32M | 6 | 11 | <0.0001% |
| Burke Steven Keith | SVP, Chief Medical Officer | 809090 0.3708% | $1.37M | 1 | 15 | |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651243 0.2985% | $1.1M | 1 | 23 | +3.18% |
| Satter Muneer A | director | 3037042 1.392% | $5.13M | 13 | 0 | <0.0001% |
| Novo A/S | 10 percent owner | 1516387 0.695% | $2.56M | 1 | 0 | +3.18% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $341.56M | |
Akebia Therapeutics, Inc. (AKBA) | $54,828,550 | 26 | -13.88% | $368.73M |
$14,865,077 | 18 | -28.56% | $353.14M | |
$276,750,010 | 16 | -7.95% | $381.52M |
AKBA Institutional Investors: Active Positions
| Increased Positions | 69 | +66.35% | 10M | +17.51% |
| Decreased Positions | 36 | -34.62% | 2M | -3.3% |
| New Positions | 24 | New | 3M | New |
| Sold Out Positions | 15 | Sold Out | 705,333 | Sold Out |
| Total Postitions | 137 | +31.73% | 68M | +14.21% |
AKBA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $27,931.00 | 6.93% | 15.1M | -99,582 | -0.66% | 2024-12-31 |
| Vanguard Group Inc | $20,136.00 | 4.99% | 10.88M | +813,902 | +8.08% | 2024-12-31 |
| State Street Corp | $11,664.00 | 2.89% | 6.3M | +3M | +83.78% | 2024-12-31 |
| Alerce Investment Management, L.P. | $10,634.00 | 2.64% | 5.75M | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $8,871.00 | 2.2% | 4.8M | +40,631 | +0.85% | 2024-12-31 |
| Renaissance Technologies Llc | $7,074.00 | 1.75% | 3.82M | +105,727 | +2.84% | 2024-12-31 |
| Morgan Stanley | $3,312.00 | 0.82% | 1.79M | +701,159 | +64.39% | 2024-12-31 |
| Northern Trust Corp | $3,118.00 | 0.77% | 1.69M | +50,542 | +3.09% | 2024-12-31 |
| Citadel Advisors Llc | $2,557.00 | 0.63% | 1.38M | +1M | New | 2024-12-31 |
| Jacobs Levy Equity Management, Inc | $2,273.00 | 0.56% | 1.23M | -805,459 | -39.6% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.